CFCs licensed in the US to treat HA and HB
| Brand (nonproprietary name) . | Technology . | Manufacturer-recommended starting dose for prophylaxis use* . |
|---|---|---|
| Factor VIII products | ||
| Kogenate FS® (octocog alfa) | Second generation: full-length recombinant | Adults: 25 IU/kg 3 times weekly; children: 25 IU/kg every other day |
| Advate® (octocog alfa) | Third generation: full-length recombinant | 20-40 IU/kg every other day |
| Kovaltry® (octocog alfa) | Third generation: full-length recombinant | Adults/adolescents: 20-40 IU/kg 2-3 times weekly; children ≤12 years: 25-50 IU/kg 2 times weekly, 3 times weekly, or every other day |
| NovoEight® (turoctocog alfa) | Third generation: B-domain truncated | Adults/adolescents: 20-50 IU/kg 3 times weekly or 20-40 IU/kg every other day; children <12 years: 25-60 IU/kg 3 times weekly or 25-50 IU/kg every other day |
| Xyntha®/ReFacto AF® (moroctocog alfa) | Third generation: B-domain deleted | Adults/adolescents: 30 IU/kg 3 times weekly; children <12 years: 25 IU/kg every other day |
| Nuwiq® (simoctocog alfa) | Fourth generation: B-domain deleted | Adults/adolescents: 30-40 IU/kg every other day; children <12 years: 30-50 IU/kg every other day or 3 times weekly |
| Hemofil M® | Plasma-derived immunoaffinity-purified FVIII | Not provided |
| Koate® | Plasma-derived containing FVIII and von Willebrand factor | Not provided |
| Humate-P® | Plasma-derived containing FVIII and von Willebrand factor | Not provided |
| Alphanate® | Plasma-derived containing FVIII and von Willebrand factor | Not provided |
| Factor IX products | ||
| BeneFIX® (nonacog alfa)† | Recombinant FIX | Age ≥16 years: 100 IU/kg weekly |
| Ixinity® (trenonacog alfa)‡ | Recombinant FIX | Adults: 40-70 IU/kg twice weekly |
| Rixubis® (nonacog gamma) | Recombinant FIX | Age ≥12 years: 40-60 IU/kg twice weekly; children <12 years: 60-80 IU/kg twice weekly |
| Alphanine | Plasma derived | Not provided |
| Brand (nonproprietary name) . | Technology . | Manufacturer-recommended starting dose for prophylaxis use* . |
|---|---|---|
| Factor VIII products | ||
| Kogenate FS® (octocog alfa) | Second generation: full-length recombinant | Adults: 25 IU/kg 3 times weekly; children: 25 IU/kg every other day |
| Advate® (octocog alfa) | Third generation: full-length recombinant | 20-40 IU/kg every other day |
| Kovaltry® (octocog alfa) | Third generation: full-length recombinant | Adults/adolescents: 20-40 IU/kg 2-3 times weekly; children ≤12 years: 25-50 IU/kg 2 times weekly, 3 times weekly, or every other day |
| NovoEight® (turoctocog alfa) | Third generation: B-domain truncated | Adults/adolescents: 20-50 IU/kg 3 times weekly or 20-40 IU/kg every other day; children <12 years: 25-60 IU/kg 3 times weekly or 25-50 IU/kg every other day |
| Xyntha®/ReFacto AF® (moroctocog alfa) | Third generation: B-domain deleted | Adults/adolescents: 30 IU/kg 3 times weekly; children <12 years: 25 IU/kg every other day |
| Nuwiq® (simoctocog alfa) | Fourth generation: B-domain deleted | Adults/adolescents: 30-40 IU/kg every other day; children <12 years: 30-50 IU/kg every other day or 3 times weekly |
| Hemofil M® | Plasma-derived immunoaffinity-purified FVIII | Not provided |
| Koate® | Plasma-derived containing FVIII and von Willebrand factor | Not provided |
| Humate-P® | Plasma-derived containing FVIII and von Willebrand factor | Not provided |
| Alphanate® | Plasma-derived containing FVIII and von Willebrand factor | Not provided |
| Factor IX products | ||
| BeneFIX® (nonacog alfa)† | Recombinant FIX | Age ≥16 years: 100 IU/kg weekly |
| Ixinity® (trenonacog alfa)‡ | Recombinant FIX | Adults: 40-70 IU/kg twice weekly |
| Rixubis® (nonacog gamma) | Recombinant FIX | Age ≥12 years: 40-60 IU/kg twice weekly; children <12 years: 60-80 IU/kg twice weekly |
| Alphanine | Plasma derived | Not provided |